EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot

NCT03791593 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Heart Failure With Reduced Ejection Fraction

Interventions

DRUG: Evolocumab

Sponsor

Fundació Institut Germans Trias i Pujol